<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606800</url>
  </required_header>
  <id_info>
    <org_study_id>8908B-059</org_study_id>
    <nct_id>NCT01606800</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)</brief_title>
  <acronym>START 4</acronym>
  <official_title>Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks)
      versus standard 48 week treatment in previously untreated adult participants with chronic
      hepatitis C (CHC) genotype 4 infection who achieve rapid virologic response (RVR), defined
      as HCV ribonucleic acid (RNA) negativity after 4 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Achieving Sustained Virologic Response (SVR)</measure>
    <time_frame>At 24 weeks after the completion of therapy (between Week 48 and Week 72)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>44 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + ribavirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + ribavirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN alfa-2b</intervention_name>
    <description>Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week</description>
    <arm_group_label>44 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
    <arm_group_label>20 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Ribavirin 200 mg capsules administered orally daily based on weight</description>
    <arm_group_label>44 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
    <arm_group_label>20 Weeks of PEG-IFN alfa-2b + RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is ≥40 kg and ≤120 kg weight

          -  Participant and participant's partner(s) must each agree to use acceptable methods of
             contraception for at least 2 weeks prior to Day 1 and continue until at least 6
             months after last dose of study medication, or longer if dictated by local
             regulations.

          -  Previously documented CHC genotype 4 infection

          -  Liver biopsy or fibrotest and fibroscan with histology consistent with CHC and no
             other etiology and with hepatic fibrosis scores (F0, F1, F2, F3).

        Exclusion Criteria:

          -  Co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus

          -  Treatment for hepatitis C with any investigational medication

          -  Treatment with any investigational drug within 30 days of the screening visit

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of clinical ascites, bleeding varices, or hepatic encephalopathy

          -  Autoimmune hepatitis or a history of autoimmune disease

          -  Hepatic fibrosis score F4

          -  Severe pre-existing cardiac disease, including unstable or uncontrolled cardiac
             disease in the previous six months

          -  Autoimmune hepatitis or a history of autoimmune disease

          -  Thyroid disease uncontrolled with conventional treatment

          -  Epilepsy and/or compromised central nervous system (CNS) function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Egypt</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 4, 2015</lastchanged_date>
  <firstreceived_date>May 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
